Relmada Therapeutics, INC.: management transactions · United States · SEC (Form 4)

About Relmada Therapeutics, INC.

Relmada Therapeutics, Inc. is a clinical-stage biopharmaceutical company listed on the Nasdaq (United States) under the ticker RLMD. For French-speaking investors, it fits the profile of a classic high-risk, high-upside small-cap healthcare name, where valuation is driven primarily by clinical execution, regulatory progress, and financing capacity rather than current product revenues. The company was founded in 2004 and is headquartered in Coral Gables, Florida, in the United States. Its strategic focus is on developing differentiated therapies in oncology and selected central nervous system indications, supported by a management team with experience in drug development, clinical operations, and regulatory strategy. ([relmada.com](https://www.relmada.com/for-investors?utm_source=openai)) Relmada’s lead program is NDV-01, an intravesical sustained-release formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer (NMIBC). The product is designed to provide prolonged bladder exposure and controlled local drug release while simplifying in-office administration. The company has disclosed FDA alignment on two registrational pathways, and NDV-01 is progressing toward a Phase 3 RESCUE registrational program expected to start in mid-2026. This program is the main value driver in the near to medium term. Relmada is also advancing sepranolone, a candidate that modulates GABA-A receptor activity to target compulsive behaviors, with a Phase 2 trial planned in Prader-Willi syndrome. ([relmada.com](https://www.relmada.com/?utm_source=openai)) From a competitive standpoint, Relmada operates in a crowded biotech landscape dominated by large pharmaceutical companies, specialized oncology players, and numerous clinical-stage peers. Its potential edge lies in NDV-01’s formulation-based differentiation, the commercial and medical attractiveness of NMIBC, and a development strategy focused on areas where unmet need remains high and treatment options are limited or suboptimal. At the same time, the company remains exposed to the standard risks of development-stage biotech: clinical failure, safety issues, regulatory setbacks, funding needs, and dilution risk. ([relmada.com](https://www.relmada.com/?utm_source=openai)) Relmada’s geographic footprint is largely U.S.-based, with operations centered in Florida and a Nasdaq listing in the United States. Recent catalysts include an oversubscribed approximately $160 million PIPE financing announced in March 2026, which strengthened the balance sheet and is expected to support NDV-01’s Phase 3 development. The company has also reported Phase 2 data for NDV-01, provided a positive regulatory update confirming FDA alignment on study design for two separate indications, and issued first-quarter 2026 business and financial updates. For investors in Europe, RLMD should be viewed as a speculative biotech story whose medium-term outcome will depend mainly on upcoming clinical milestones and regulatory validation, rather than near-term earnings power. ([relmada.com](https://www.relmada.com/for-investors/news/detail/333/relmada-therapeutics-announces-oversubscribed-160-0?utm_source=openai))